Nano-medicine Formation

Biologics Encapsulation

Rapid, one-step process for encapsulation of biologics

There are a large percentage of new biologic drug prospects that have high aqueous solubility, but are susceptible to rapid clearance, preventing the development of suitable biologic formulations. Flash NanoPrecipitation (FNP) is a process which through rapid mixing stabilizes a compound of interest such as drugs into a nano-sized, polymer-stabilized delivery vehicle. Previously, FNP has been limited to the encapsulation of hydrophobic molecules (logP>6) based on hydrophobic interactions. However, extending FNP to encapsulating hydrophilic molecules such as biologics (i.e., proteins) would provide a rapid method to expand the clinical applications for biologic-based therapies. Others have also approached encapsulating biologics with FNP; however, they require multiple steps, which is in contrast to the process presented here.

The technology

Virginia Commonwealth University researchers have developed a rapid, single-step process using FNP to encapsulate biologics using a cationic polyelectrolyte and tannic acid (TA). The intermolecular interactions for forming the nanoparticles allows for high biologic loading, which increases the bioavailability. The benefit of increased bioavailability is a high delivery dosage. Such an approach would be used for protein therapies, cancer treatments, and diseases that require high specificity.


Encapsulation biologics process [View Image]

Figure 1: Diagram of a model system example encapsulating BSA, a model protein, using FNP with TA to form an anionic precipitate that is stabilized with a cationic polymer stabilizer (i.e., polyethylenimine or PEI).  The mechanism of self-assembly is affected by the molecular weight of the PEI.

Download PDF

Benefits:

  • One step process
  • Increased stability > 1 week 
  • High biologics loading

Applications:

  • Protein therapies
  • Cancer treatments
  • Diseases with specificity:
    • Arthritis
    • Heart disease
    • Crohn's disease

Licensing

PartnerEASY (Express)

  • $10,000 conversion fee
  • Royalty rate of 3% (2% for VA companies)
  • For VA start-ups, royalty free for first $100,000 in sales; 2% thereafter

Additional information

Investigators:

Christina Tang, Ph.D.
Shani Levit

Patent status:

Patent Pending: U.S. and foreign rights available

License status:

This technology is available for licensing to industry for further development and commercialization

Category:

Engineering and physical science

VCU Tech #:

19-058

Contact us about
this technology

Koffi Selom Egbeto, M.S.
Licensing Associate
egbetok@vcu.edu
(804) 827-2213